Fukumoto Kota, Nguyen Tran B, Chiba Shigeru, Sakata-Yanagimoto Mamiko
Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
Department of Hematology, Faculty of Medicine, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
Cancer Sci. 2018 Mar;109(3):490-496. doi: 10.1111/cas.13393. Epub 2017 Nov 27.
Angioimmunoblastic T-cell lymphoma (AITL) is an age-related malignant lymphoma, characterized by immune system-dysregulated symptoms. Recent sequencing studies have clarified the recurrent mutations in ras homology family member A (RHOA) and in genes encoding epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2), DNA methyl transferase 3 alpha (DNMT3A) and isocitrate dehydrogenase 2, mitochondrial (IDH2), as well as those related to the T-cell receptor signaling pathway in AITL. In this review, we focus on how this genetic information has changed the understanding of the developmental process of AITL and will in future lead to individualized therapies for AITL patients.
血管免疫母细胞性T细胞淋巴瘤(AITL)是一种与年龄相关的恶性淋巴瘤,其特征为免疫系统失调症状。最近的测序研究已经明确了AITL中Ras同源家族成员A(RHOA)以及编码表观遗传调节因子的基因(如四氢甲基胞嘧啶双加氧酶2(TET2)、DNA甲基转移酶3α(DNMT3A)和线粒体异柠檬酸脱氢酶2(IDH2))的复发性突变,以及与AITL中T细胞受体信号通路相关的突变。在本综述中,我们重点关注这些遗传信息如何改变了对AITL发育过程的理解,并将在未来为AITL患者带来个体化治疗。